Tarsus Pharmaceuticals (TARS) Non-Current Debt (2022 - 2026)
Tarsus Pharmaceuticals (TARS) posted quarterly Non-Current Debt of $72.6 million for Q1 2026, up 0.85% year-over-year from $72.0 million in Q1 2025, and little changed quarter-over-quarter from $72.4 million in Q4 2025.
Tarsus Pharmaceuticals (TARS) Non-Current Debt (2022 - 2026) Analysis & Trends
Tarsus Pharmaceuticals' Non-Current Debt history runs 5 years deep, the most recent figure standing at $72.6 million for Q1 2026.
- In Q1 2026, Non-Current Debt rose 0.85% year-over-year to $72.6 million; the TTM figure through Mar 2026 stood at $72.6 million (up 0.85% YoY), while the FY2025 annual figure was $72.4 million, up 0.83% from the prior year.
- Non-Current Debt for Q1 2026 stood at $72.6 million, roughly flat from $72.4 million in the prior quarter.
- The five-year high for Non-Current Debt was $72.6 million in Q1 2026, with the low at $19.2 million in Q1 2022.
- The 5-year median for Non-Current Debt is $29.9 million (2024), against an average of $46.6 million.
- The sharpest annual moves came in 2024 and 2025: Non-Current Debt surged 190.88% in 2024, then advanced 0.77% in 2025.
- Tarsus Pharmaceuticals' Non-Current Debt stood at $19.4 million in 2022, then surged by 53.44% to $29.8 million in 2023, then surged by 140.94% to $71.8 million in 2024, then increased by 0.83% to $72.4 million in 2025, then climbed by 0.22% to $72.6 million in 2026.
- Business Quant data shows TARS's Non-Current Debt at $72.6 million in Q1 2026, $72.4 million in Q4 2025, and $72.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Tarsus Pharmaceuticals | 2.99 Bn | 2.54 Bn | 161.80 Mn | 72.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 72.76 Mn |
| Mar 31, 2026 | 72.60 Mn |
| Dec 31, 2025 | 72.44 Mn |
| Sep 30, 2025 | 72.28 Mn |
| Jun 30, 2025 | 72.13 Mn |
| Mar 31, 2025 | 71.98 Mn |
| Dec 31, 2024 | 71.85 Mn |
| Sep 30, 2024 | 71.71 Mn |
| Jun 30, 2024 | 71.58 Mn |
| Mar 31, 2024 | 29.93 Mn |
| Dec 31, 2023 | 29.82 Mn |
| Sep 30, 2023 | 29.71 Mn |
| Jun 30, 2023 | 24.61 Mn |
| Mar 31, 2023 | 24.52 Mn |
| Dec 31, 2022 | 19.43 Mn |
| Sep 30, 2022 | 19.36 Mn |
| Jun 30, 2022 | 19.26 Mn |
| Mar 31, 2022 | 19.18 Mn |